China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
Reuters
Jan 30
China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
Jan 30 (Reuters) - CSPC Pharmaceutical Group 1093.HK said on Friday it had entered an agreement with UK drugmaker AstraZeneca AZN.L for the development of innovative long-acting peptide medicines for obesity and weight-related conditions.
AstraZeneca will obtain access to some of the programmes and platforms of the Chinese biotechnology firm's pharmaceutical in exchange for an upfront payment of $1.2 billion, it added.
(Reporting by Sherin Sunny in Bengaluru; Editing by Rashmi Aich)
((Sherin.Sunny@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.